Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
PHILADELPHIA, June 14, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an...
-
Permits All Eligible Individuals with Late-Onset Pompe Disease Access to AT-GAA Prior to Marketing Authorization in the UK Positive Scientific Opinion Under Early Access to Medicines Scheme (EAMS)...
-
PHILADELPHIA, May 28, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Goldman...
-
PHILADELPHIA, May 21, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the 16th...
-
Galafold® (migalastat) Performance Reflects Continued Strong Adoption in All Key Global Regions; On-Track to Achieve Revenue Guidance of $300M-$315M 1Q21 Total Galafold Revenue of $66.4M Driven by...
-
PHILADELPHIA, May 07, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the...
-
Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization PHILADELPHIA, May 06, 2021 (GLOBE...
-
PHILADELPHIA, May 05, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the acceptance of two abstracts for presentation at the American Society of Gene & Cell Therapy...
-
Existing Data Support Regulatory Submissions Submissions to Seek Approval in both ERT Naïve and ERT Switch Pompe Patients Completion of Rolling Biologics License Application On-Track by end of 2Q21...
-
PHILADELPHIA, April 28, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel...